CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 34 enrolled
Drug / intervention
liraglutidedrug
Likely dose
liraglutide 0.6mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01832532
NCT01832532Phase 2Completed

Pilot 2: Glucagon-like Peptide-1 in Sleep Disordered Breathing

Children's Hospital Medical Center, Cincinnati·interventional·Posted Apr 16, 2013·Updated Oct 20, 2020

In Brief

A Phase 2 clinical trial evaluating liraglutide for Sleep Apnea and Sleep Disordered Breathing. Completed, enrolled 34 participants across 1 site.

Detailed Summary

This is an open label, controlled study. The investigators are studying if the FDA approved diabetes medicine liraglutide (Victoza®) can improve sleep apnea in adults. This study is testing liraglutide in 20 adults without diabetes that are diagnosed with sleep apnea.The treatment group will be compared to a control group of 10 adults without diabetes who have sleep apnea but will not use liraglutide. Both groups will continue receiving standard of care for their sleep apnea as prescribed by their managing sleep physician throughout their study participation. Everyone in the study will have two study visits and one overnight sleep study for research. Subjects who have not had a recent sleep study but otherwise qualify for the study, will have an additional research sleep study to determine the baseline severity of their sleep apnea. The study visits include fasting blood samples and breathing tests (pulmonary function test and hypercapnic challenge). There will be weekly phone visits that include a questionnaire on sleepiness. The group that takes liraglutide will check their blood sugar two times a day while on the medicine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 16, 2013
Enrollment StartApr 1, 2013
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 13.2 years ago

Interventions

liraglutidedrug

daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose